NEW YORK (GenomeWeb) — Chinese startup Cure Genetics announced today that it has raised $17 million in a Series A financing round. The round was led by Qiming Venture Partners and included investments from CTS Capital and Ascendin Investment.
NEW YORK-based Cure Genetics has raised $17m in series A funding, led by Qiming Venture Partners, with investment from CTS Capital and Ascendin Investment. The start-up, which uses gene editing to develop medicines and molecular diagnostics, will use the funds to improve its technology platforms, to fund regulatory filings and clinical trials, and to expand its pipeline.